JP2019513015A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513015A5
JP2019513015A5 JP2018547941A JP2018547941A JP2019513015A5 JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5 JP 2018547941 A JP2018547941 A JP 2018547941A JP 2018547941 A JP2018547941 A JP 2018547941A JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513015A (ja
JP6987072B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021958 external-priority patent/WO2017156488A2/en
Publication of JP2019513015A publication Critical patent/JP2019513015A/ja
Publication of JP2019513015A5 publication Critical patent/JP2019513015A5/ja
Priority to JP2021194152A priority Critical patent/JP7469284B2/ja
Application granted granted Critical
Publication of JP6987072B2 publication Critical patent/JP6987072B2/ja
Priority to JP2023198762A priority patent/JP7755634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547941A 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用 Active JP6987072B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021194152A JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306354P 2016-03-10 2016-03-10
US62/306,354 2016-03-10
PCT/US2017/021958 WO2017156488A2 (en) 2016-03-10 2017-03-10 Activin type 2 receptor binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194152A Division JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2019513015A JP2019513015A (ja) 2019-05-23
JP2019513015A5 true JP2019513015A5 (OSRAM) 2020-04-23
JP6987072B2 JP6987072B2 (ja) 2021-12-22

Family

ID=59790844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018547941A Active JP6987072B2 (ja) 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用

Country Status (19)

Country Link
US (4) US10307455B2 (OSRAM)
EP (2) EP3426680B1 (OSRAM)
JP (3) JP6987072B2 (OSRAM)
KR (4) KR102866147B1 (OSRAM)
CN (2) CN116284392A (OSRAM)
AU (1) AU2017230091B2 (OSRAM)
BR (1) BR112018067813A2 (OSRAM)
CA (1) CA3015277A1 (OSRAM)
DK (1) DK3426680T3 (OSRAM)
ES (1) ES2987504T3 (OSRAM)
FI (1) FI3426680T3 (OSRAM)
HR (1) HRP20241557T1 (OSRAM)
HU (1) HUE069467T2 (OSRAM)
LT (1) LT3426680T (OSRAM)
PL (1) PL3426680T3 (OSRAM)
PT (1) PT3426680T (OSRAM)
RS (1) RS66251B1 (OSRAM)
SI (1) SI3426680T1 (OSRAM)
WO (1) WO2017156488A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3426680T3 (pl) 2016-03-10 2025-03-31 Acceleron Pharma Inc. Białka wiążące receptor aktywiny typu 2 i ich zastosowania
JP7669291B2 (ja) * 2019-05-30 2025-04-28 アクセレロン ファーマ インコーポレーテッド Actrii結合性タンパク質及びその使用
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
WO2021222322A1 (en) * 2020-04-28 2021-11-04 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
CN117794562A (zh) * 2021-06-11 2024-03-29 阿塞勒隆制药公司 ActRII蛋白及其用途
WO2024044782A1 (en) 2022-08-26 2024-02-29 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546806C2 (OSRAM) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
BR9709006A (pt) 1996-05-20 1999-08-03 Novo Nordisk As Processo para obter á partir de sumbstrato protéico um hidrolisado enriquecido com ácido glutámico livre e/ou resíduos de ácido glutámico libados por peptídeo produto alimentício e aditivo de racão animal
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
ATE373712T1 (de) 1997-10-03 2007-10-15 Chugai Pharmaceutical Co Ltd Natürlicher menschlicher antikörper
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
MA26040A1 (fr) 2001-01-05 2004-04-01 Pfizer Des anticorps pour recepteur i de facteur de croissance insulinique
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
KR20050059332A (ko) 2002-11-07 2005-06-17 이뮤노젠 아이엔씨 항-씨디33 항체와 이를 이용한 급성 골수성 백혈병의치료방법
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (gdf8) 저해제의 용도
WO2005116052A2 (en) 2004-04-27 2005-12-08 Research Development Foundation ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2007109668A2 (en) 2006-03-20 2007-09-27 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of novel receptors of pth and fragments thereof
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) * 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
LT2370463T (lt) 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
ITAN20090010U1 (it) 2009-04-27 2010-10-28 Arnaldo Sorci Staffa di bloccaggio protettiva
SG174273A1 (en) * 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
ES2869580T3 (es) 2009-09-09 2021-10-25 Acceleron Pharma Inc Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal
WO2011056997A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
JP2013510441A (ja) 2009-11-05 2013-03-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エッチングされたミラーを伴う半極性{20−21}iii族窒化物系レーザダイオード
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
WO2012012759A2 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ, インコーポレイテッド Actriia結合剤およびその使用
TW201249867A (en) 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
MX2014000578A (es) * 2011-07-14 2014-04-30 Pfizer Tratamiento con anticuerpos anti-pcsk9.
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
EP2793925B1 (en) 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9029510B2 (en) * 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
US9453080B2 (en) 2012-06-11 2016-09-27 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
US20160000020A1 (en) 2013-02-01 2016-01-07 Brilliantservice Co., Ltd. Cultivation system, cultivation program, and cultivation method
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
US20170260275A1 (en) 2014-12-08 2017-09-14 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
PL3426680T3 (pl) 2016-03-10 2025-03-31 Acceleron Pharma Inc. Białka wiążące receptor aktywiny typu 2 i ich zastosowania
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2024026159A5 (OSRAM)
JP2019513015A5 (OSRAM)
AU2021200348B2 (en) Binding molecules with modified J-chain
CN109311971B (zh) 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途
TWI767174B (zh) 異二聚免疫球蛋白
KR101852915B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
TWI815306B (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
CA3064298A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2019515676A5 (OSRAM)
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
KR20230141817A (ko) 이중특이 항체
KR20240070496A (ko) 활성화된 간 성상세포(hscs)의 고갈 및 이의 용도
JP2021500895A5 (OSRAM)
CN113166239B (zh) 抗il-17a抗体及其应用
WO2019080909A1 (en) TARGETING THERAPEUTIC ANTIBODY RANKL
JPWO2020243448A5 (OSRAM)
CN115811987A (zh) 抗神经酰胺抗体
AU2023291634C1 (en) Follistatin fusion proteins
JPWO2022253314A5 (OSRAM)
TW202535947A (zh) CD33抗體、CD33/Vδ2多特異性抗體及其用途
HK40057229B (en) Anti-il-17a antibody and use thereof
HK1212719B (zh) 全人源抗rankl抗体